These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27381749)

  • 1. Molecular changes in the postmortem parkinsonian brain.
    Toulorge D; Schapira AH; Hajj R
    J Neurochem; 2016 Oct; 139 Suppl 1():27-58. PubMed ID: 27381749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial dysfunction in Parkinson's disease.
    Bose A; Beal MF
    J Neurochem; 2016 Oct; 139 Suppl 1():216-231. PubMed ID: 27546335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current perspective of mitochondrial biology in Parkinson's disease.
    Ammal Kaidery N; Thomas B
    Neurochem Int; 2018 Jul; 117():91-113. PubMed ID: 29550604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Importance of
    Vos M; Klein C
    Cells; 2021 Mar; 10(3):. PubMed ID: 33800736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease.
    Calì T; Ottolini D; Brini M
    Biofactors; 2011; 37(3):228-40. PubMed ID: 21674642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimer's disease, Parkinson's disease.
    Tan SH; Karri V; Tay NWR; Chang KH; Ah HY; Ng PQ; Ho HS; Keh HW; Candasamy M
    Biomed Pharmacother; 2019 Mar; 111():765-777. PubMed ID: 30612001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.
    Banerjee R; Starkov AA; Beal MF; Thomas B
    Biochim Biophys Acta; 2009 Jul; 1792(7):651-63. PubMed ID: 19059336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of genetic and environmental Parkinson's disease models reveals a common role of mitochondrial protection pathways.
    Soreq L; Ben-Shaul Y; Israel Z; Bergman H; Soreq H
    Neurobiol Dis; 2012 Mar; 45(3):1018-30. PubMed ID: 22198569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases.
    Mattson MP; Pedersen WA; Duan W; Culmsee C; Camandola S
    Ann N Y Acad Sci; 1999; 893():154-75. PubMed ID: 10672236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial defects and neurodegeneration in mice overexpressing wild-type or G399S mutant HtrA2.
    Casadei N; Sood P; Ulrich T; Fallier-Becker P; Kieper N; Helling S; May C; Glaab E; Chen J; Nuber S; Wolburg H; Marcus K; Rapaport D; Ott T; Riess O; Krüger R; Fitzgerald JC
    Hum Mol Genet; 2016 Feb; 25(3):459-71. PubMed ID: 26604148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein and mitochondrial dysfunction in Parkinson's disease.
    Mullin S; Schapira A
    Mol Neurobiol; 2013 Apr; 47(2):587-97. PubMed ID: 23361255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial dysfunction-induced H3K27 hyperacetylation perturbs enhancers in Parkinson's disease.
    Huang M; Lou D; Charli A; Kong D; Jin H; Zenitsky G; Anantharam V; Kanthasamy A; Wang Z; Kanthasamy AG
    JCI Insight; 2021 Sep; 6(17):. PubMed ID: 34494552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging (and converging) pathways in Parkinson's disease: keeping mitochondrial wellness.
    Cieri D; Brini M; Calì T
    Biochem Biophys Res Commun; 2017 Feb; 483(4):1020-1030. PubMed ID: 27581196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balance is the challenge--the impact of mitochondrial dynamics in Parkinson's disease.
    Burbulla LF; Krebiehl G; Krüger R
    Eur J Clin Invest; 2010 Nov; 40(11):1048-60. PubMed ID: 20735469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial-Associated Membranes in Parkinson's Disease.
    Hattori N; Arano T; Hatano T; Mori A; Imai Y
    Adv Exp Med Biol; 2017; 997():157-169. PubMed ID: 28815529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2012 Nov; 53(9):1791-806. PubMed ID: 22967820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?
    Bisaglia M; Filograna R; Beltramini M; Bubacco L
    Ageing Res Rev; 2014 Jan; 13():107-14. PubMed ID: 24389159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SUMO-regulated mitochondrial function in Parkinson's disease.
    Guerra de Souza AC; Prediger RD; Cimarosti H
    J Neurochem; 2016 Jun; 137(5):673-86. PubMed ID: 26932327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson's Disease.
    Prasad KN
    Curr Aging Sci; 2017; 10(3):177-184. PubMed ID: 28042771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial pathology in Parkinson's disease.
    Schapira AH
    Mt Sinai J Med; 2011; 78(6):872-81. PubMed ID: 22069211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.